Approaches to overcome EGFR-TKI resistance in NSCLC by reversing EMT are currently under investigation, including the targeting of CD70, cyclin-dependent kinase 7 (CDK7), lipid metabolism pathways, and fibroblast growth factor receptor 1 (FGFR1) (125–128). The gene discussed is FGFR1; the disease is non-small cell lung carcinoma.